Nuveen
RPRX icon

Nuveen’s Royalty Pharma RPRX Stock Holding History

Nuveen’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.9M Buy
1,157,659
+351,848
+44% +$18.3M 0.02% 570
2026
Q1 		$38.7M Buy
805,811
+78,456
+11% +$3.44M 0.01% 770
2025
Q4 		$28.1M Buy
727,355
+1,205
+0.2% +$46K 0.01% 946
2025
Q3 		$25.6M Sell
726,150
-6,974
-1% -$252K 0.01% 994
2025
Q2 		$26.4M Sell
733,124
-158,254
-18% -$5.24M 0.01% 935
2025
Q1 		$27.7M Sell
891,378
-53,223
-6% -$1.69M 0.01% 929
2024
Q4 		$24.1M Buy
944,601
+8,802
+0.9% +$233K 0.01% 1050
2024
Q3 		$26.5M Buy
935,799
+3,358
+0.4% +$93K 0.01% 989
2024
Q2 		$24.6M Sell
932,441
-45,265
-5% -$1.25M 0.01% 1001
2024
Q1 		$29.7M Sell
977,706
-26,755
-3% -$789K 0.01% 922
2023
Q4 		$28.2M Sell
1,004,461
-26,798
-3% -$736K 0.01% 926
2023
Q3 		$28M Sell
1,031,259
-11,193
-1% -$332K 0.01% 849
2023
Q2 		$32M Buy
1,042,452
+35,919
+4% +$1.22M 0.01% 784
2023
Q1 		$36.3M Sell
1,006,533
-10,222
-1% -$379K 0.01% 702
2022
Q4 		$40.2M Buy
1,016,755
+26,617
+3% +$1.11M 0.02% 624
2022
Q3 		$39.8M Buy
990,138
+9,590
+1% +$410K 0.02% 625
2022
Q2 		$41.2M Buy
980,548
+63,117
+7% +$2.59M 0.02% 625
2022
Q1 		$35.7M Buy
917,431
+6,479
+0.7% +$254K 0.01% 815
2021
Q4 		$36.3M Sell
910,952
-76,583
-8% -$2.98M 0.01% 862
2021
Q3 		$35.7M Sell
987,535
-207,347
-17% -$8.06M 0.01% 876
2021
Q2 		$49M Sell
1,194,882
-3,705
-0.3% -$158K 0.01% 749
2021
Q1 		$52.3M Buy
1,198,587
+793,209
+196% +$37.6M 0.02% 702
2020
Q4 		$20.3M Buy
405,378
+143,379
+55% +$6.08M 0.01% 1259
2020
Q3 		$11M Buy
+261,999
New +$11.2M ﹤0.01% 1462

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's RPRX Position: Q2 2026 in Review

Nuveen increased its Royalty Pharma (RPRX) stake by 44% in Q2 2026, buying an estimated $18.3M and bringing the position to 1,157,659 shares worth $64.9M. The position accounts for 0.02% of the portfolio, ranked #570.

Nuveen first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Nuveen held 1,157,659 shares of Royalty Pharma worth $64.9M as of Q2 2026.
  • Nuveen bought 351,848 Royalty Pharma shares in Q2 2026, an estimated $18.3M.
  • Royalty Pharma made up 0.02% of Nuveen's portfolio in Q2 2026, its #570 holding.
  • Nuveen first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.